Supernus Pharmaceuticals ROA 2011-2024 | SUPN
Current and historical return on assets (ROA) values for Supernus Pharmaceuticals (SUPN) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Supernus Pharmaceuticals ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2024-09-30 |
$0.06B |
$1.34B |
4.50% |
| 2024-06-30 |
$0.01B |
$1.32B |
0.39% |
| 2024-03-31 |
$-0.02B |
$1.30B |
-1.24% |
| 2023-12-31 |
$0.00B |
$1.28B |
0.07% |
| 2023-09-30 |
$0.03B |
$1.29B |
1.65% |
| 2023-06-30 |
$0.04B |
$1.29B |
2.65% |
| 2023-03-31 |
$0.05B |
$1.79B |
3.02% |
| 2022-12-31 |
$0.06B |
$1.70B |
3.63% |
| 2022-09-30 |
$0.04B |
$1.69B |
2.26% |
| 2022-06-30 |
$0.06B |
$1.70B |
3.53% |
| 2022-03-31 |
$0.07B |
$1.64B |
4.58% |
| 2021-12-31 |
$0.05B |
$1.69B |
3.42% |
| 2021-09-30 |
$0.08B |
$1.56B |
5.41% |
| 2021-06-30 |
$0.10B |
$1.57B |
6.63% |
| 2021-03-31 |
$0.11B |
$1.51B |
7.45% |
| 2020-12-31 |
$0.13B |
$1.50B |
8.99% |
| 2020-09-30 |
$0.13B |
$1.51B |
9.72% |
| 2020-06-30 |
$0.12B |
$1.49B |
9.62% |
| 2020-03-31 |
$0.12B |
$1.19B |
10.35% |
| 2019-12-31 |
$0.11B |
$1.16B |
10.38% |
| 2019-09-30 |
$0.11B |
$1.11B |
10.16% |
| 2019-06-30 |
$0.11B |
$1.06B |
10.53% |
| 2019-03-31 |
$0.10B |
$1.03B |
10.90% |
| 2018-12-31 |
$0.11B |
$0.98B |
12.41% |
| 2018-09-30 |
$0.10B |
$0.92B |
13.09% |
| 2018-06-30 |
$0.09B |
$0.85B |
13.99% |
| 2018-03-31 |
$0.07B |
$0.83B |
14.75% |
| 2017-12-31 |
$0.06B |
$0.42B |
15.44% |
| 2017-09-30 |
$0.06B |
$0.39B |
16.73% |
| 2017-06-30 |
$0.10B |
$0.35B |
32.62% |
| 2017-03-31 |
$0.10B |
$0.32B |
33.80% |
| 2016-12-31 |
$0.09B |
$0.31B |
36.11% |
| 2016-09-30 |
$0.08B |
$0.29B |
37.88% |
| 2016-06-30 |
$0.03B |
$0.22B |
13.52% |
| 2016-03-31 |
$0.02B |
$0.19B |
10.23% |
| 2015-12-31 |
$0.01B |
$0.19B |
8.63% |
| 2015-09-30 |
$0.01B |
$0.17B |
7.37% |
| 2015-06-30 |
$0.01B |
$0.15B |
3.60% |
| 2015-03-31 |
$0.01B |
$0.14B |
4.84% |
| 2014-12-31 |
$-0.01B |
$0.14B |
-9.67% |
| 2014-09-30 |
$-0.04B |
$0.13B |
-34.50% |
| 2014-06-30 |
$-0.06B |
$0.09B |
-55.27% |
| 2014-03-31 |
$-0.09B |
$0.10B |
-76.56% |
| 2013-12-31 |
$-0.09B |
$0.11B |
-81.61% |
| 2013-09-30 |
$-0.08B |
$0.12B |
-77.39% |
| 2013-06-30 |
$-0.07B |
$0.13B |
-77.42% |
| 2013-03-31 |
$-0.06B |
$0.08B |
-68.75% |
| 2012-12-31 |
$-0.05B |
$0.09B |
-66.20% |
| 2012-09-30 |
$0.05B |
$0.07B |
80.33% |
| 2012-06-30 |
$0.05B |
$0.08B |
115.25% |
| 2012-03-31 |
$0.05B |
$0.04B |
218.56% |
| 2011-12-31 |
$0.05B |
$0.05B |
377.78% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$2.003B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
